Literature DB >> 15701719

The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells.

Yuval Shaked1, Dave Cervi, Manuela Neuman, Limor Chen, Giannoula Klement, Crystal R Michaud, Mehran Haeri, Brian J Pak, Robert S Kerbel, Yaacov Ben-David.   

Abstract

The stromal compartments of hematopoietic organs (eg, spleen) are known to influence the viability and growth of diseased hematopoietic progenitors. Here we have used Friend murine leukemia virus (F-MuLV)-induced erythroleukemia to investigate factors of the splenic microenvironment that may make it fertile for the expansion and survival of malignant erythroblasts. We found that splenectomized, erythroleukemic mice exhibited extended survival compared with age-matched sham controls. In vitro, the proliferation of primary erythroleukemic cells cocultured with leukemic-derived splenic adherent cells or their conditioned media was found to be significantly higher than that observed in cocultures with healthy-derived adherent splenic cells. Cytokine protein arrays revealed that F-MuLV-infected splenocytes secreted elevated levels of interleukin-6 (IL-6), vascular endothelial growth factor-A (VEGF-A), macrophage chemoattractant protein-5 (MCP-5), soluble tumor necrosis factor receptor-1 (sTNFR1), IL-12p70, tumor necrosis factor-alpha (TNF-alpha), and IL-2 over normal splenocytes. Medium supplemented with both VEGF-A and MCP-5 could sustain proliferation of primary erythroleukemic cells in vitro, and significant proliferative suppression was observed upon addition of neutralizing antibodies to either of these factors. Furthermore, in vivo administration of a neutralizing antibody to VEGF-A extended survival times of erythroleukemic mice in comparison with controls. These findings suggest that VEGF-A and MCP-5 are potentially pivotal paracrine mediators occurring within the diseased splenic microenvironment capable of promoting disease acceleration and expansion of erythroleukemic blasts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15701719      PMCID: PMC1895028          DOI: 10.1182/blood-2004-08-3210

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Molecular mechanisms involved in long-term maintenance of erythroleukaemia cells by stromal cells.

Authors:  P R Harrison; R J Nibbs; C Bartholomew; J O'Prey; J Qiu; M Walker; A M Clark; N Leslie; W Ostertag
Journal:  Leukemia       Date:  1997-04       Impact factor: 11.528

Review 2.  The spleen in myeloproliferative disorders.

Authors:  J M Goldman; I Nolasco
Journal:  Clin Haematol       Date:  1983-06

3.  Friend leukemia as a multiple-step disease.

Authors:  P Tambourin; F Wendling; F Moreau-Gachelin
Journal:  Blood Cells       Date:  1981

Review 4.  The multiple roles of tumour stroma.

Authors:  N Wernert
Journal:  Virchows Arch       Date:  1997-06       Impact factor: 4.064

5.  Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia.

Authors:  A R Perez-Atayde; S E Sallan; U Tedrow; S Connors; E Allred; J Folkman
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

6.  Cloned stromal cell lines derived from human Whitlock/Witte-type long-term bone marrow cultures.

Authors:  J R Novotny; U Duehrsen; K Welch; J E Layton; J S Cebon; A W Boyd
Journal:  Exp Hematol       Date:  1990-08       Impact factor: 3.084

Review 7.  Splenectomy in lymphoproliferative disorders: a report on 70 cases and review of the literature.

Authors:  J E Coad; E Matutes; D Catovsky
Journal:  Leuk Lymphoma       Date:  1993-07

8.  Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study.

Authors:  D Ribatti; A Vacca; B Nico; M Fanelli; L Roncali; F Dammacco
Journal:  Eur J Haematol       Date:  1996 Jan-Feb       Impact factor: 2.997

Review 9.  Molecular biology of Friend viral erythroleukemia.

Authors:  D Kabat
Journal:  Curr Top Microbiol Immunol       Date:  1989       Impact factor: 4.291

10.  Murine monocyte chemoattractant protein (MCP)-5: a novel CC chemokine that is a structural and functional homologue of human MCP-1.

Authors:  M N Sarafi; E A Garcia-Zepeda; J A MacLean; I F Charo; A D Luster
Journal:  J Exp Med       Date:  1997-01-06       Impact factor: 14.307

View more
  15 in total

1.  Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia.

Authors:  David Cervi; Yuval Shaked; Mehran Haeri; Tatiana Usenko; Christina R Lee; Jody J Haigh; Andras Nagy; Robert S Kerbel; Eitan Yefenof; Yaacov Ben-David
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

2.  Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.

Authors:  Yuval Shaked; Urban Emmenegger; Shan Man; Dave Cervi; Francesco Bertolini; Yaacov Ben-David; Robert S Kerbel
Journal:  Blood       Date:  2005-07-05       Impact factor: 22.113

3.  The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL.

Authors:  Alessandra Di Grande; Sofie Peirs; Paul D Donovan; Maaike Van Trimpont; Julie Morscio; Beatrice Lintermans; Lindy Reunes; Niels Vandamme; Steven Goossens; Hien Anh Nguyen; Arnon Lavie; Richard B Lock; Jochen H M Prehn; Pieter Van Vlierberghe; Triona Ní Chonghaile
Journal:  Blood Adv       Date:  2021-04-13

4.  Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance.

Authors:  Elias D Bührer; Michael A Amrein; Stefan Forster; Stephan Isringhausen; Christian M Schürch; Salil S Bhate; Tess Brodie; Joel Zindel; Deborah Stroka; Mohamad Al Sayed; César Nombela-Arrieta; Ramin Radpour; Carsten Riether; Adrian F Ochsenbein
Journal:  Leukemia       Date:  2022-09-26       Impact factor: 12.883

5.  Splenectomy suppresses growth and metastasis of hepatocellular carcinoma through decreasing myeloid-derived suppressor cells in vivo.

Authors:  Xin Long; Jian Wang; Jian-Ping Zhao; Hui-Fang Liang; Peng Zhu; Qi Cheng; Qian Chen; Yan-Hui Wu; Zhan-Guo Zhang; Bi-Xiang Zhang; Xiao-Ping Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

6.  Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.

Authors:  E Weisberg; A K Azab; P W Manley; A L Kung; A L Christie; R Bronson; I M Ghobrial; J D Griffin
Journal:  Leukemia       Date:  2011-12-20       Impact factor: 11.528

7.  Notch1-induced T cell leukemia can be potentiated by microenvironmental cues in the spleen.

Authors:  Shihui Ma; Yingxu Shi; Yakun Pang; Fang Dong; Hui Cheng; Sha Hao; Jing Xu; Xiaofan Zhu; Weiping Yuan; Tao Cheng; Guoguang Zheng
Journal:  J Hematol Oncol       Date:  2014-11-04       Impact factor: 17.388

8.  Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.

Authors:  Ellen Weisberg; Renee D Wright; Douglas W McMillin; Constantine Mitsiades; Arghya Ray; Rosemary Barrett; Sophia Adamia; Richard Stone; Ilene Galinsky; Andrew L Kung; James D Griffin
Journal:  Mol Cancer Ther       Date:  2008-04-29       Impact factor: 6.261

9.  Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia.

Authors:  Pedro Ramos; Carla Casu; Sara Gardenghi; Laura Breda; Bart J Crielaard; Ella Guy; Maria Franca Marongiu; Ritama Gupta; Ross L Levine; Omar Abdel-Wahab; Benjamin L Ebert; Nico Van Rooijen; Saghi Ghaffari; Robert W Grady; Patricia J Giardina; Stefano Rivella
Journal:  Nat Med       Date:  2013-03-17       Impact factor: 53.440

10.  Chronic psychological stress activates BMP4-dependent extramedullary erythropoiesis.

Authors:  Sanja Vignjević; Mirela Budeč; Dragana Marković; Dragoslava Dikić; Olivera Mitrović; Slavko Mojsilović; Sanja Vranješ Durić; Vesna Koko; Bojana Beleslin Cokić; Vladan Cokić; Gordana Jovčić
Journal:  J Cell Mol Med       Date:  2013-11-27       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.